Developing the next generation of CAR-T cell therapies to treat solid cancers
Currus Biologics is developing its proprietary BEAT technology for solid tumors
CAR-T cell therapy works by extracting a patient’s T-cells and genetically engineering these cells to produce chimeric antigen receptors (CARs) that can be used to specifically seek out and destroy cancer cells after infusion back into the patient.
The BEAT technology enables the use of CAR-T cell therapies for the treatment of solid tumour indications, which remain largely impervious to treatment with current CAR-T cell technologies.
Currus Biologics’ BEAT overcomes many of the challenges presented with traditional CAR-T cell therapies when treating solid tumours.
